Dr. Suzanne Gazda, MD, Neurology Institute of San Antonio offers a blueprint for brain health. What is the hypothesis? A multidomain lifestyle change—diet, exercise, sleep, social/brain engagement—paired with judicious therapeutics can lower dementia risk and bolster cognition. This is a clinician's synthesis, not a single trial. It curates converging signals that lifestyle matters, surveys repurposed drugs and anti-amyloid therapies and urges a prevention-first care model. The argument is compelling for public health; causal proof remains uneven across topics.

Study Design & Methods: A Curated Map, not a Single Road

This work functions as a narrative review/position paper. It integrates epidemiology (e.g., education, sleep, obesity, diabetes), environment (air pollution, sunlight/Vit D), risk alleles (APOE4), and behavioral levers (socialization, "brain training"), along with updates on anti-amyloid monoclonals and repurposed drugs (fasudil, fluticasone, ibudilast, lithium, semaglutide, sildenafil). Lifestyle evidence includes randomized multidomain trials (e.g., POINTER-style designs) plus observational cohorts; therapeutic sections draw on preclinical, mechanistic, retrospective, and early clinical signals.

Suzanne Gazda, MD

Source: NISA

Findings: Where the Signal Is Strong—and Where It's Preliminary

If you want the most reliable, low-risk way to protect your brain, start with the basics you control. Multidomain lifestyle programs that blend a Mediterranean or MIND-style diet with regular exercise, solid sleep, and steady cognitive and social engagement keep showing up as winners. Across studies—including randomized trials—the gains aren't miraculous, but they are real: slower cognitive decline and a lower chance of developing dementia over time. Think of it as compounding interest for your brain—small, steady deposits that add up.

Your personal risk can also be nudged by biology and environment. Carrying the APOE4 gene variant raises vulnerability, and that added risk seems to interact with other hits like smoking, heavy alcohol use, prior concussions, and metabolic disease. Air pollution is another lever—plausible, common, and importantly, modifiable through policy and personal choices (like avoiding high-pollution outdoor workouts when alerts are issued).

Metabolism matters, too. Midlife obesity and type 2 diabetes consistently track with a higher risk of dementia later on. The flip side is encouraging: better blood-sugar control and healthy weight loss correlate with better cognitive trajectories. In short, what helps your heart and pancreas likely helps your brain.

On the drug front, there's buzz about repurposed medicines—lithium, semaglutide, sildenafil, fasudil, ibudilast, even intranasal steroids. Early signals are intriguing and worth studying, but they're not ready for routine use against dementia. Meanwhile, the FDA-approved anti-amyloid antibodies lecanemab and donanemab can slow decline in early Alzheimer's. Benefits are incremental—not cures—and they come with real trade-offs, including close monitoring for ARIA (brain swelling or microbleeds).

A final word of caution: the science is still messy in places. Studies don't always look the same or measure the same things (heterogeneity), some are observational and can't prove cause and effect (confounding), and many drug signals come from small or preclinical work. Selection bias, survivorship bias, and "healthy-user" effects can also make an intervention look better than it truly is. The takeaway? Double down on lifestyle now, manage known risks, and watch the therapeutics space with curiosity—and a healthy dose of skepticism.

Limitations & Disclosures

Limitations: Narrative (not systematic) synthesis; variable study quality; reliance on associative data for several claims; preclinical/retrospective drug signals; generalizability may differ by genetics, socioeconomic factors, and care access.
Disclosures: Not stated in the manuscript excerpt. *TrialSite* treats absence of a disclosure statement as unknown and factors this into conservatively weighted scoring.

Conclusion & Implications: Prevention First, Evidence Always

A prevention-centric model—move, eat smart, sleep well, connect, train the brain, and manage cardiometabolic risk—is low-risk and high-plausibility. Anti-amyloid drugs can help carefully selected early-stage patients; repurposed agents warrant prospective, adequately powered trials. The strongest immediate policy lever is scaling primary-care-led brain-health programs with validated tools and clear patient education—while continuing rigorous trials to separate correlation from causation.

And Gazda would likely state that protecting cognitive strength begins not in the lab, but in everyday choices made early and often.

Citation: Gazda S. *Preserving America's Cognitive Strength*. Neurology Institute of San Antonio. October 2025. (References include: Lancet Dementia Prevention Commission 2024; JAMA US POINTER RCT 2025; selected mechanistic/observational studies on APOE4, obesity/diabetes, air pollution, and anti-amyloid trials.)